NuCana plc N04A.F Stock
NuCana plc Price Chart
NuCana plc N04A.F Financial and Trading Overview
NuCana plc stock price | 0.22 EUR |
Previous Close | 0.67 EUR |
Open | 0.66 EUR |
Bid | 0.66 EUR x 0 |
Ask | 0.71 EUR x 0 |
Day's Range | 0.66 - 0.66 EUR |
52 Week Range | 0.59 - 1.93 EUR |
Volume | 1K EUR |
Avg. Volume | 17 EUR |
Market Cap | 36.14M EUR |
Beta (5Y Monthly) | 1.238028 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.89 EUR |
N04A.F Valuation Measures
Enterprise Value | 4.11M EUR |
Trailing P/E | N/A |
Forward P/E | -1.5000001 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 1.0784315 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -0.102 |
Trading Information
NuCana plc Stock Price History
Beta (5Y Monthly) | 1.238028 |
52-Week Change | 6.40% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.93 EUR |
52 Week Low | 0.59 EUR |
50-Day Moving Average | 0.74 EUR |
200-Day Moving Average | 1.02 EUR |
N04A.F Share Statistics
Avg. Volume (3 month) | 17 EUR |
Avg. Daily Volume (10-Days) | 100 EUR |
Shares Outstanding | 52.39M |
Float | 34.13M |
Short Ratio | N/A |
% Held by Insiders | 0.71% |
% Held by Institutions | 31.54% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -42.17% |
Return on Equity (ttm) | -69.60% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -40188000 EUR |
Net Income Avi to Common (ttm) | -31485000 EUR |
Diluted EPS (ttm) | -0.66 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 31M EUR |
Total Cash Per Share (mrq) | 0.6 EUR |
Total Debt (mrq) | 602K EUR |
Total Debt/Equity (mrq) | 1.9 EUR |
Current Ratio (mrq) | 2.733 |
Book Value Per Share (mrq) | 0.612 |
Cash Flow Statement
Operating Cash Flow (ttm) | -24873000 EUR |
Levered Free Cash Flow (ttm) | -18147500 EUR |
Profile of NuCana plc
Country | Germany |
State | N/A |
City | Edinburgh |
Address | 3 Lochside Way |
ZIP | EH12 9DT |
Phone | 44 13 1357 1111 |
Website | https://www.nucana.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 28 |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer. The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Its pipeline also comprises NUC-7738, a transformation of 3'-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Q&A For NuCana plc Stock
What is a current N04A.F stock price?
NuCana plc N04A.F stock price today per share is 0.22 EUR.
How to purchase NuCana plc stock?
You can buy N04A.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NuCana plc?
The stock symbol or ticker of NuCana plc is N04A.F.
Which industry does the NuCana plc company belong to?
The NuCana plc industry is Biotechnology.
How many shares does NuCana plc have in circulation?
The max supply of NuCana plc shares is 52.86M.
What is NuCana plc Price to Earnings Ratio (PE Ratio)?
NuCana plc PE Ratio is 0.00000000 now.
What was NuCana plc earnings per share over the trailing 12 months (TTM)?
NuCana plc EPS is 0 EUR over the trailing 12 months.
Which sector does the NuCana plc company belong to?
The NuCana plc sector is Healthcare.